become drug resistant to hormonal therapy, Sulf1/Sulf2 inhibition could be an alternative therapeutic approach to target such tumours by down-regulating RTK-mediated cell signalling.
Introduction
Mammary tumours represent the most common cancer amongst women, but like many other cancers it is molecularly heterogeneous and highly variable in its therapeutic response and metastatic properties (Engstrøm et al. 2013 ). Molecular subtyping of this cancer provides some prognostic information regarding the most likely clinical outcomes. The most widely used markers for tissue biopsy characterisation include the positive or negative expression of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER-2), often described as triplepositive or triple-negative cancers. Many triple-positive tumours are successfully treated over a number of years although a proportion of them become drug resistant over time and thus effectively untreatable as are a large majority of the drug non-responsive triple-negative cancers (Clarke et al. 2015) . It would thus help to discern the key drivers of breast tumour growth to enable targeting alternative signalling pathways to overcome drug-resistant cell survival.
Cell signalling is one of the key drivers of tumour growth, but most cancers activate not one but multiple signalling pathways. Targeting one specific cell signalling pathway often activates alternative pathways. While it is desirable to devise specific targets, the inhibition of multiple pathways may in some cases be more effective. For Abstract The relative roles of SULF1 and SULF2 enzymes in tumour growth are controversial, but short SULF1/SULF2 splice variants predominate in human mammary tumours despite their non-detectable levels in normal mammary tissue. Compared with the normal, the level of receptor tyrosine kinase (RTK) activity was markedly increased in triple-positive mammary tumours during later stages of tumour progression showing increased p-EGFR, p-FGFR1 and p-cMet activity in triple-positive but not in triple-negative tumours. The abundance of catalytically inactive short SULF1/SULF2 variants permits high levels of HS sulphation and thus growth driving RTK cell signalling in primary mammary tumours. Also observed in this study, however, was increased N-sulphation detected by antibody 10E4 indicating that not only 6-O sulphation but also N-sulphation may contribute to increased RTK cell signalling in mammary tumours. The levels of such increases in not only SULF1/SULF2 but also in pEGFR, pFGFR1, p-cMet and Smad1/5/8 signalling were further enhanced following lymph node metastasis. The over-expression of Sulf1 and Sulf2 variants in mammary tumour-derived MDA-MB231 and MCF7 cell lines by transfection further confirms Sulf1-/Sulf2-mediated differential modulation of growth. The short variants of both Sulf1 and Sulf2 promoted FGF2-induced MDA-MB231 and MCF7 in vitro growth while full-length Sulf1 inhibited growth supporting in vivo mammary tumour cell signalling patterns of growth. Since a number of mammary tumours 1 3 example, targeting co-receptors such as heparan sulphate proteoglycans (HSPGs) or their modifying enzymes may inhibit multiple cancer signalling pathways considering that the expression of HSPGs and their associated enzymes markedly changes during tumour growth. Heparan sulphate (HS) chains of glycosaminoglycans (GAGs) in HSPGs are made up of repeating disaccharide units of glucuronic/ iduronic acid and glucosamine that show further modifications of their properties generated by deacetylation, epimerisation and sulphation at the N-, 3-O and 6-O positions of glucosamine and the 2-O position of the iduronic acid residue. Changes in their HS sulphation patterns can exert differential functional effects on cell signalling and thus drive not only regulated normal development but also dysregulated tumour growth. Of particular interest amongst these changes is the 6-O sulphate group of the HS chains that has been shown to be associated with the regulation of a number of growth factor signalling pathways (Lamanna et al. 2007) . The significance of 6-O sulphation in cell signalling has been further highlighted by the discovery of extracellular editing of HS sulphation by two cell surface sulphatases, Sulf1 (qSulf1) and Sulf2, which specifically hydrolyse glucosamine-6S groups of the HS chain (Dhoot et al. 2001; Morimoto-Tomita et al. 2002) . Reduction in 6-O HS sulphation promotes certain cell signalling pathways such as Wnt and GDNF but inhibits others, for example tyrosine kinase receptor-mediated FGF-2, HB-EGF and HGF pathways. Sulf1/Sulf2 regulation of 6-O HS sulphation thus has the potential to control cell growth and migration by regulating the activities of specific cell signalling pathways.
Both Sulf1 and Sulf2 have been shown to be up-regulated in a number of cancer types (Bret et al. 2011; Gill et al. 2012 Gill et al. , 2014 Nawroth et al. 2007; Lemjabbar-Alaoui et al. 2010; Phillips et al. 2012 ) although some others have reported the down-regulation of Sulf1 in mammary tumours (Lai et al. 2006; Narita et al. 2007; Lai et al. 2008) since they describe Sulf1 as a tumour suppressor but Sulf2 as a tumour enhancer. Some such differences may relate to in vivo primary tumours versus in vitro cell line comparisons. While a number of tumour studies report the investigation of primary tumours, many also invest a lot of effort in tumour-derived cell lines, with each cell line representing a single patient considering that no two tumours are identical and even a single tumour demonstrates extensive spatial and temporal evolvement over time (Gill et al. 2014) . The limited in vitro cell line analyses thus may not replicate the in vivo tumour growth patterns. The in vitro growth of cell lines also lacks in vivo competition for survival due to unsustainable active in vivo growth and stromal infiltration. The cell lines themselves can also evolve during different culture conditions and one has to bear in mind that normal mammary tissue does not express detectable levels of either Sulf1or Sulf2 proteins although low level of mRNA can be detected using multiple RT-PCR amplification cycles (Morimoto-Tomita et al. 2005) . Cell lines nevertheless are a useful tool to investigate the role of different components in cell signalling and growth.
The additional problem of Sulf1/Sulf2 analysis of any pathological tissue and particularly the tumour tissues relates to the generation of multiple splice variants with different functional activities (Sahota and Dhoot 2009; Gill et al. 2011 Gill et al. , 2012 Gill et al. , 2014 that so far has received little attention. Lack of attention to splice variant diversity is even more misleading for those tumours in which the short variants of both Sulf1 and Sulf2 predominate during most stages of growth. The lack of catalytic activity in such shorter variants can completely change their cell signalling function. The present study therefore was undertaken to determine the nature of Sulf1 and Sulf2 variants in mammary tumours and to determine whether their ectopic expression alters tumour growth. This study demonstrates the abundance of shorter variants of both Sulf1 and Sulf2 in mammary tumours although low levels of full-length isoforms were also detectable in such tissues. These tumours also demonstrate the up-regulation of RTK-mediated cell signalling pathways whose activities would be protected by shorter Sulf variants unlike the inhibitory effects of full-length Sulf1 on RTK-mediated pathways. The in vitro ectopic expression of full-length and short Sulf1 and Sulf2 splice variants further supports their differential functions in mammary tumour-derived cell lines and their patterns of growth although most primary tumours as well as cell lines often express more than one variant in the same or adjacent in vivo stromal cells.
Materials and methods

Tissue samples and immunocytochemical staining procedure
Human mammary tumour tissue arrays containing both normal and cancer tissue samples were obtained from US Biomax and included two or three cores from each patient sample. This analysis also included some other samples provided by Addenbroke's Hospital, Cambridge, as part of another study (Gill et al. 2011 ). The number of samples for each group was: normal: 11, hyperplasia: 6, benign: 6, triple-positive invasive ductal carcinoma stage I: 35, stage II: 172, stage III: 75; triple-negative invasive ductal carcinoma stage I: 6, stage II: 22, stage III: 12; number of triple-positive invasive ductal carcinomas in primary location: 50 and following metastasis to lymph node: 50. The pattern of SULF1/SULF2 expression in such samples was examined using antibodies to these enzymes, the specificities of which have previously been described (Gill et al. 2011 (Gill et al. , 2012 (Gill et al. , 2010 Sahota and Dhoot 2009 ). Single or double immunofluorescence was used to stain paraffin sections of human tissues with different SULF1, SULF2 and some commercial antibodies (Gill et al. 2010; 2014) listed in Table 1 . The binding of mouse primary antibodies was detected using Alexa Fluor 488 fluorochrome-conjugated goat anti-mouse IgG diluted 1/400. Binding to total SULF1 (full-length and all splice variants) by SULF1 antibody C (1/200) was visualised using goat anti-rabbit biotinylated IgG followed by streptavidinconjugated Alexa Fluor 594. Sequential double immunofluorescence using two different rabbit antibodies included labelling exon specific antibodies with Alexa Fluor 488 followed by total SULF1 or SULF2 antibodies labelled with Alexa Fluor 594 (Fig. 1c) . The double immunofluorescence procedure using two different rabbit antibodies sequentially always included staining with an exon specific antibody detected by Alexa Fluor 488 label first. The second part of double immunofluorescence always included staining with an antibody to total SULF1 (antibody C) or total SULF2 (antibody D). To ensure no cross-reaction with the two rabbit antibodies, the staining patterns were also ascertained with individual primary antibodies before their application in the double immunofluorescence procedure. Sections treated with pre-immune rabbit sera were similarly incubated with fluorochromelabelled secondary antibodies as controls (not shown). All fluorochrome-labelled secondary antibodies were diluted 1/400. All appropriately diluted (Table 1) primary antibody reactions were incubated overnight at 4 °C followed by secondary antibody incubations for 1 h each at room temperature. Labelled tissue sections were mounted in fluorescent mounting medium (Sigma Aldrich) containing 2.5 μg/ml DAPI for nuclear visualisation and photographed using a Leica DM4000B fluorescent microscope. Quantification of the individual fluorescent images was carried out using Volocity software by measuring average pixel count/image.
Cell culture and transfection
Based on our splice variant analysis of canine and human Sulf1 and Sulf2 genes described previously (Gill et al. 2011 (Gill et al. , 2012 (Gill et al. , 2014 , human Sulf1 and Sulf2 cDNA constructs cloned in pcDNA3 were transfected for overexpression in MCF7 and MDA-MB231 cell lines obtained from ATCC. Such cell lines purchased from ATCC were grown in RPMI (MCF7) or Dulbecco's modified Eagle's (DMEM) medium (MDA.MB231) with 10 %FCS. Sulf1/ Sulf2 variants were transfected with an EGFP expression vector while the control cells were transfected with EGFP/ pcDNA3 alone using the Bio-Rad TransFectin reagent. To enrich the mixed population of transfected cells, the normal growth medium was changed to DMEM/10 %FCS with 800 µg/ml G418 following 48 h of growth in the normal medium. The Sulf1/Sulf2 over-expression by transfection was confirmed by the RT-PCR analysis. Such transfected cells were used for in vitro and in vivo assays following 2-6 weeks of growth in G418 containing medium. For in vitro proliferation assays, 10,000 cells/well were seeded in multiple 24-well plates and the trypsinised cells were counted after 5 days of culture. In addition to each sample consisting of a minimum of three replicates for each stage, each experiment was repeated three times.
RT-PCR
To examine the expression of Sulf1 and Sulf2 splice variants in cell lines, total RNA was prepared from mammary tumour cell lines MCF7 and MDA-MB231 using Trizol. RNA was also prepared from these cell lines following their transfection with only EGFP (as control) and with full-length or short Sulf1 or Sulf2 variant as described before (Gill et al. 2014) . Equivalent amount of total RNA (1 μg) for each sample was reverse-transcribed into cDNA using SuperScript II reverse transcriptase (Invitrogen), using random primers (Invitrogen, Paisley, UK) for RT-PCR analysis. The PCR of cDNA was carried out using primers to exons 5 and 9 of the catalytic domain that we have shown to splice out exons 6-8 in different combinations in our earlier study (Gill et al. 2014; Zaman et al. 2016 ). The primers 5′-CGAGGTTCAGAGGACGGATA-3′ and 5′-GCCTCTCCACAGAATCATCC-3′ were used to amplify 804-bp fragment of catalytic domain, nucleotides 83-886 bp of Sulf1. Primers 5′-CAACTGTGTTCTCCCTGCTGGGT-3′ 1 3
and 5′-CTGGAGCATGTTGGTGAATTCC-3′ were used to amplify a region of Sulf2 catalytic domain, nucleotides 38-843 (Zaman et al. 2016) . PCR fragments following 40 amplification cycles separated in 2 % agarose gels were cut out and purified to verify their identity by DNA sequencing (GATC Biotech). Primers 5′-CTATGAGCTGCCTGACG-GTC-3′ and 5′-AGTTTCATGGATGCCACAGG-3′ were used to amplify 114-bp β-actin (nucleotides 798-912 bp) to normalise the sample loading.
Statistical analysis
Statistical analysis was preformed using either a one-way ANOVA or a two-way ANOVA, where data depicting a P value <0.05 were considered statistically significant. To enable multiple comparisons, a Tukey's test was used to determine significant variation between Sulf transfects to their eGFP controls or between full-length Sulf isoforms and their shorter variants. 
Results
Expression patterns of SULF1/SULF2 variants in mammary tumours
Neither SULF1 and nor SULF2 is detectable in normal mammary tissues using the immunohistochemical staining procedure (Figs. 1, 2 ). Low-level SULF1 and or SULF2 expression is, however, detectable in some benign and hyperplastic samples (Figs. 1, 2) . The onset of SULF1 expression and its persistence during all stages becomes increasingly clear in both triplepositive and triple-negative malignant tissues (Figs. 1, 2). SULF2 expression is also observed in all mammary tumours although the level of this enzyme was lower in triple-positive compared with triple-negative tumours (Fig. 2) . The shorter variants of both SULF1 and SULF2 enzymes were the most abundant isoforms in all mammary tumours. The levels of full-length SULF2 and particularly SULF1 were low in all such tumours. While SULF1 expression appeared to be mainly in the epithelial or mesenchymal cells during all stages, the expression of SULF2 appeared relatively more abundant in the stromal tissue in both triple-positive and triple-negative tumours (Fig. 2) . The level of SULF1 in triple-positive tissues was considerably higher than levels of SULF2 in such tumours while both SULF1 and SULF2 predominated in triple-negative samples. The levels of full-length SULF2 and particularly full-length SULF1 in such tumours in comparison were much lower. 
Cell signalling in mammary tumours
To determine whether the low-level expression of fulllength SULF1/SULF2 compared with much higher expression of their shorter variants impacted specific cell signalling pathways, we examined the activities of not only BMP and Hedgehog cell signalling but also markers for a number of tyrosine kinase receptor-mediated cell signalling pathways during different stages of both triple-positive and triple-negative tumour growth. Compared with the normal, immunohistochemical analysis demonstrated increased activation of BMP signalling investigated by the expression of p-Smad 1/5/8 staining as well as increased RTK staining for p-EGFR, p-FGFR1 and p-cMet (Fig. 3) . Semi-quantitative analysis of immunohistochemical staining using Volocity software highlighted the onset of such signalling in all triple-positive samples with particularly increased levels during stages II and III (Fig. 4) . While the level of p-Smad 1/5/8 and p-cMet in triple-positive samples was low during stage I, the levels of p-EGFR and p-FGFR1 were high even during stage I. Unlike triplepositive tumours, the levels of p-FGFR1 and particularly p-EGFR in contrast were low in triple-negative tumours (Fig. 4) . While the level of BMP signalling also increased in triple-negative tumours, the level of p-cMet in triplenegative samples showed only a moderate increase. The AKT and ERK1/2 cascades are triggered by growth factors and cytokines acting through receptor tyrosine kinases. Investigation of such downstream targets of RTK signalling pathways further indicated the active involvement of RTK cell signalling as a large majority of the tumours showed high levels of pERK and pAKT activity (Fig. 5) . A small proportion of the tumours, however, also showed greatly reduced level of pAKT and pERK activity not only in triple-negative (Fig. 5 ) but also in some triple-positive tumours (Fig. 5 ). Hedgehog signalling investigated by ptc1 receptor expression did not show any specific changes in such tumours.
Increased SULF1/SULF2 expression and RTK-mediated cell signalling following mammary tumour metastasis to lymph node
We also examined whether SULF1/SULF2 expression or cell signalling activities changed in a set of primary triplepositive mammary tumours that had metastasised to lymph nodes when compared with the original tumour in its primary location. SULF1 as well as SULF2 expression was maintained and quantitatively enhanced following metastasis to lymph node although the level of SULF2 decreased during late stage metastasis (Fig. 6 ). The nature of SULF1/ SULF2 splice variant following metastasis did not change as the metastasised cells still predominantly expressed the shorter variants. The semi-quantitative analysis of immunohistochemical staining using Volocity software also showed significant increases in HSPG sulphation, p-EGFR, pFGFR1, p-cMet and BMP signalling analysed by p-Smad1/5/8 analysis during both earlier (stage II) and later (stage III) stages of metastasis (Fig. 7) .
The differential cell signalling roles of Sulf1/Sulf2 variants in some mammary tumour-derived cell lines
To examine the role of Sulf1 and Sulf2 variants in tumour growth, triple-negative MDA-MB231 and oestrogen receptor-positive MCF7 mammary tumour cell lines were individually transfected with full-length and shorter Sulf1 and Sulf2 variants. MDA-MB231 cells express only a trace amount of full-length Sulf1 under normal culture conditions but not any Sulf2 (Fig. 8) since the DNA sequencing of a shorter band (indicated by an asterisk) in Sulf2 lane showed it to be a non-specific zinc finger protein. The RT-PCR analysis of MCF7 cell line in contrast did not only confirm it to express high level of Sulf2 as reported by others (Uchimura et al. 2006 ) but also detect the expression of a short Sulf1 variant that has not been previously reported (Fig. 8b) . The DNA sequencing of this fragment confirmed it to lack exons 6-8. The Sulf1/Sulf2 gene transfection of these cell lines inducing not only mRNA but also protein expression was apparent in all cultures as is shown for MDA-MB231cells (Fig. 8c ) that normally do not express any Sulf2. The over-expression of full-length Sulf1 (HS1) in MDA-MB231 cells inhibited its in vitro growth while the overexpression of the shorter Sulf1 (HS1-678) variant promoted growth. The over-expression of full-length (HS2) as well as its shorter variant (HS2-678) in MDA-MB231cells promoted its growth although the level of increase with HS2 was higher than with HS2-678 transfection (Fig. 8d ).
The addition of FGF2 to such transfected cells promoted growth in EGFP-and HS1-678-transfected cells and with only a marginal increase in HS2-678-transfected cells but reduced growth in HS2-transfected cells with a lower inhibition observed in HS1-transfected cells (Fig. 8d) .
The over-expression of Sulf1 and Sulf2 variants in MCF7 cells promoted growth not only in HS1-678 and HS2-678 cells but also in HS2-transfected cells but with inhibition observed in HS1-transfected cells (Fig. 8e) . The addition of FGF2 to such transfected cells demonstrated increased growth in EGFP-and HS1-678-transfected cells but with no significant further growth but preservation in HS2-678-transfected cells (Fig. 8e) .
The addition of cyclopamine to all MDA-MB231-transfected cells markedly inhibited in vitro growth while the addition of SHH ligand promoted growth in only the control EGFP-transfected cells but inhibition in both Fig. 6 a, b Patterns of SULF1 and SULF2 expression in triplepositive invasive ductal carcinomas in their primary location in mammary tumour and the same tumour following metastasis to lymph node. SULF1 is detected using antibody A against exon 6 (Alexa Fluor 488) and antibody C against total SULF1 (Alexa Fluor 594). The superimposed pictures show exon 6-containing SULF1 as yellow and total SULF1 as red. SULF2 is detected using antibody N against exon 6 (Alexa Fluor 488) and antibody D against total SULF2 (Alexa Fluor 594). The superimposed pictures show exon 6-containing SULF2 as yellow and total SULF2 as red. Also shown in this figure is semi-quantitative analysis of changes in SULF1 a1 and SULF2 b1 (yellow full length; red total) full-length and shorter Sulf1-and Sulf2-transfected cells (Fig. 8f) . The addition of cyclopamine to all MCF7-transfected cells also markedly inhibited in vitro growth while the addition of SHH ligand promoted growth not only in EGFP but also in HS1-and HS2-transfected cells but demonstrated significant inhibition in HS1-678 and HS2-678 transfected cells (Fig. 8g) .
Discussion
The present study demonstrated SULF1 expression not only in triple-positive but also in triple-negative mammary tumours during all stages of tumour growth although the SULF1 level was much lower in benign tumours. This contrasts with little or no SULF1 expression in normal mammary tissue. The major SULF1 variant expressed in these tumours was the shorter variant lacking catalytically active exon 6 although low levels of full-length enzyme were also detected in some tumours. Up-regulation of SULF2 was also observed in both triple-positive and triple-negative mammary tumours, with the level of SULF2 expression being higher in triple-negative than triple-positive. Although SULF2 was barely detectable in normal mammary tissue, significant levels of SULF2 were also observed in benign and hyperplastic mammary tissues. As was the case with SULF1, it was the shorter SULF2 splice variant lacking catalytically active exon 6 that predominated in such tumours although low, but significant levels of fulllength SULF2 were also apparent in some samples. Alternative splicing of exons can alter protein function and thus increase the functional diversity of proteins. Such splicing could contribute to functional versatility of proteins to increase the diversity of interaction networks. Shorter variants could affect tumour growth by titrating out the activity of the full-length inhibitory variant by competing for ligand or receptor binding. High levels of both SULF1 and SULF2 in not only triple-positive but also in triple-negative mammary tumours highlight the SULF1/SULF2 independence from oestrogen signalling. This differs from oestrogen receptor-mediated EGFR signalling that was barely detectable in triple-negative tumours unlike its high activity in oestrogen-positive tumours. This thus indicates variation in the mechanism of SULF1 and SULF2 function in triple-positive versus triple-negative tumours. Short SULF1/ SULF2 variants in triple-positive tumours are ideally suited to promote 6-O sulphate requiring receptor tyrosine kinase signalling, but it is not clear which signalling pathways are promoted by shorter variants in triple-negative tumours. The level of BMP and Hedgehog signalling was higher in triple-negative than triple-positive tumours that may also be facilitated by short variants or the balance of full-length and shorter variants in these tumours. Enhanced Wnt signalling and Notch signalling has also been reported to play a role Fig. 7 a Pattern of pEGFR1 expression in triple-positive invasive ductal carcinoma in its primary location in mammary tumour and the same tumour following metastasis to lymph node, with p-EGFR staining appearing green with blue DAPI nuclear counterstain. b-g show semi-quantitative analysis of changes in N-sulphation b and different growth factor signalling activities (pEGFR, pFGFR1, p-cMet, ptc1, Smad 1, 5, 8) as indicated in triple-positive invasive ductal carcinoma stages II and III in primary mammary tumour location and following metastasis to lymph node, **p < 0.001, *p < 0.01. The number of samples for this analysis was: triple-positive invasive ductal carcinomas in primary location: 50 and following metastasis to lymph node: 50 in triple-negative tumours (Jamdade et al. 2015; Koval et al. 2016; King et al. 2012 ) although Wnt signalling is believed to be promoted by full-length Sulf1 and Sulf2 genes.
The high levels of short SULF1/SULF2 variants observed during tumour growth also coincided with high levels of sulphation detected in triple-positive as well as triple-negative mammary tumours although 10E4 antibody has been reported to detect N-sulphation (David et al. 1992) and not 6-O sulphation modulated by SULF1/SULF2. The low-level sulphation in normal mammary tissue, however, is clearly and Sulf2 variant over-expression was examined on growth of such cells over 5 days in both the presence and absence of 50 ng/ml FGF2 in MDA-MB231 cells (d) and MCF7 (e) cells. Also examined was the effect of Sulf1 and Sulf2 variant over-expression on Hedgehog signalling stimulation using SHH (10 ng/ml) and inhibition by Cyclopamine (10 µM) on the growth of MDA-MB231 (f) and MCF7 (g) cells following 5 days in vitro growth, error bars: mean ± SD of samples, **p < 0.001, *p < 0.01. Each proliferation assay included a minimum of 3 replicates, and each experiment was repeated three times 1 3 not related to the presence of full-length SULF1 or SULF2 but the differential activity of the intracellular sulphotransferases. It is thus not surprising to observe increased RTKmediated cell signalling in mammary tumours, the activities of which would be enhanced by increased HS sulphation. For example, the level of EGFR and FGFR1 RTK activity was greatly increased in triple-positive but not in triplenegative samples except for some increase during stage II. The level of cMet RTK was similarly greatly increased in triple-positive mammary tumours, particularly during stages II and III while the increase was lower but still significant in triple-negative tumours. The presence of significant levels of short SULF1 and SULF2 variants would support such RTK-mediated cell signalling in mammary tumours. We nevertheless acknowledge that increased sulphation in mammary tumours observed by antibody 10E4 relates to N-sulphation and not 6-O sulphation required for many RTK-mediated cell signalling pathways. N-sulphation, however, has been reported to be important for certain cell signalling pathways. For example, defective N-sulphation of heparan sulphate proteoglycans has been shown to limit PDGF-BB binding and pericyte recruitment in vascular development (Abramsson et al. 2007 ) although SULF1 and SULF2 have also been shown to inhibit PDGF signalling by 6-O desulphation (Takashima et al. 2016 ). PDGF signalling is thus regulated by both N-sulphation and 6-O sulphation. N-sulphation or some factors requiring N-sulphation have also been shown to be important in the developing mammary gland (Bush et al. 2012) .
Of all the RTK signalling pathways investigated in this study, the EGFR RTK activity demonstrated the clearest difference in triple-positive versus triple-negative tumours. For example, while triple-positive mammary tumours demonstrated greatly increased EGFR RTK activity, triple-negative tumours despite increased sulphation did not show any EGFR activity. Differences in EGFR cell signalling in triplepositive versus triple-negative samples could relate to lack of ER signalling in these tumours. EGFR signalling despite short Sulf1 and Sulf2 abundance regulating HSPG sulphation in triple-negative tumours thus could not be promoted due to critical dependence of EGFR activity on ER signalling (Britton et al. 2006 ). Triple-negative tumours nevertheless showed some pERK and pAKT downstream signalling due presumably to some activation of cMet RTK activity although even BMP signalling has been reported to increase activities of such enzymes in some cases (Ye et al. 2009 ). For example, the BMPs have been reported to affect RTK activity indirectly by promoting VEGF activity to enhance angiogenesis in many cancer tissues (Dai et al. 2004; Deckers et al. 2002) . A family of ligands that binds ErbB receptors (ErbB1/EGFR, ErbB2/Her-2/Neu, ErbB3 and ErbB4) plays an important role in breast cancer in which such receptors are over-expressed to promote tumour growth. When activated by ligand binding, this family of ErbB/EGFR receptor tyrosine kinases induces receptor dimerisation, kinase activity and auto-phosphorylation to trigger downstream ERK1/2 and PI3K/AKT activation. Phosphorylation of such downstream signalling molecules enhances tumour cell survival and proliferation. The EGFR activity in human mammary cancers is thus implicated in regulating cell growth and survival through its differential activity via ER response. The constitutive activation of the kinase pathways, however, may bypass inhibition of EGFR/HER2 tyrosine kinases and develop insensitivity to drugs targeting these receptors. This is compatible with reported observations (Britton et al. 2006 ) that oestrogen receptor modulates EGFR/kinase signalling in some tamoxifen-resistant breast cancer cells.
To determine whether SULF variant expression also correlated with some other cell signalling pathways, the immunocytochemical analysis also detected BMP signalling as revealed by downstream p-Smad 1, 5, 8 activation in both triple-positive and triple-negative tumours although some previous studies have shown BMP signalling restricted to only triple-positive samples (Helms et al. 2005) . The precise function of BMP signalling in breast cancer, however, is still unclear since specific BMP ligands have been shown to promote as well as inhibit cancer cell growth and migration including metastasis (Alarmo 2010) although most such studies are restricted to mainly cell line analyses.
Breast cancer metastasis to lymph nodes showed further increase in not only BMP signalling but also RTK-mediated cell signalling including increased p-EGFR, p-FGFR1 and p-cMet activities. Increased RTK signalling following metastasis is also compatible with further increased expression of short SULF1 variant during both earlier and later stages and SULF2 variant increase only during earlier stage. RTK signalling is implicated in tumour invasion and metastasis but how such different signalling pathways are specifically used for tumour invasion is not clear. It is possible that increased RTK activation facilitated by increased sulphation destabilises E-cadherin adhesions to induce epithelial mesenchymal transformation (EMT) required for tumour cell metastasis to the lymph node or any other tissue (Qian et al. 2004) .
The involvement of Sulf1/Sulf2 splice variants in mammary tumour progression was further supported by our in vitro investigation of their over-expression in MCF7 and MDA-MB231 mammary tumour cell lines. The MCF7 cell line, however, unlike MDA-MB231 already expresses not only full-length Sulf2 (Uchimura et al. 2006 ) but also a shorter variant of Sulf1 that we observed in the present study. Nevertheless, full-length Sulf1 unlike the shorter Sulf1 variant inhibited MCF7 in vitro growth, whereas over-expression of both full-length and shorter Sulf2 promoted growth but with less clearer effects on FGF2 activity. It is also remarkable that the growth of MCF7 cell line was inhibited by full-length Sulf1 considering that it already expresses high level of full-length Sulf2, thus highlighting some inherent differences in Sulf1 and Sulf2 activities despite their high level of homology and similarity of function. It is possible that the expression of fulllength Sulf2 in MCF7 is sufficiently counteracted by the presence of short Sulf1 variant so that full-length Sulf1 can exert its inhibitory activity. Sulf1 over-expression in MDA-MB231 cell line that normally does not express any Sulfs with the exception of a trace amount of full-length Sulf1 demonstrated clear differences in their effects on cellular growth as full-length Sulf1 inhibited while short Sulf1 variant promoted in vitro growth. Unlike the full-length Sulf1, over-expression of full-length Sulf2 did not inhibit MDA-MB231 in vitro growth but instead promoted growth as did the shorter variant of Sulf2. The differential inhibitory effect of full-length Sulf1 in comparison with growth enhancing effect of shorter Sulf1 was also apparent from their differential inhibitory and stimulatory effects on FGF signalling. While both short and full-length Sulf2 promoted MDA-MB231 growth, the FGF2 activity was inhibited by full-length but not the shorter Sulf2 variant. The mechanism of such full-length Sulf1 and Sulf2 differences is not clear considering that both these enzymes have similar 6-O desulphation function and nor can it be explained by their differential cell surface signalling and ECM sequestering activities observed in vivo tissues. The SULF1 and SULF2 functional similarities observed in normal tissues thus not always hold true in tumour tissues due presumably to multiple mutations. Understanding the interactions between different components of cell signalling pathways could provide new avenues in devising novel therapeutic strategies for drug-resistant mammary tumours. This study shows that both SULF1 and SULF2 are over-expressed in breast cancer in which they could promote tumour growth and metastasis. Targeting SULF1/SULF2 may offer alternative strategies to develop novel cancer therapies. In conclusion, short SULF variants predominate in mammary tumours to stimulate growth and metastasis by protecting HS sulphation that enhances RTK-mediated cell signalling.
